WO2008083239A3 - Compositions and methods for stimulating an immune response - Google Patents
Compositions and methods for stimulating an immune response Download PDFInfo
- Publication number
- WO2008083239A3 WO2008083239A3 PCT/US2007/088979 US2007088979W WO2008083239A3 WO 2008083239 A3 WO2008083239 A3 WO 2008083239A3 US 2007088979 W US2007088979 W US 2007088979W WO 2008083239 A3 WO2008083239 A3 WO 2008083239A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- immune response
- stimulating
- methods
- promoting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3413—Diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007339773A AU2007339773B2 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for stimulating an immune response |
JP2009544272A JP2011502954A (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for stimulating an immune response |
CA002673752A CA2673752A1 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for stimulating an immune response |
EP07869990A EP2109455A2 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for stimulating an immune response |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87731906P | 2006-12-27 | 2006-12-27 | |
US60/877,319 | 2006-12-27 | ||
US94974207P | 2007-07-13 | 2007-07-13 | |
US60/949,742 | 2007-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008083239A2 WO2008083239A2 (en) | 2008-07-10 |
WO2008083239A3 true WO2008083239A3 (en) | 2008-08-28 |
Family
ID=39521467
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/088979 WO2008083239A2 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for stimulating an immune response |
PCT/US2007/088960 WO2008083228A2 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for treating inflammation and auto-immune diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/088960 WO2008083228A2 (en) | 2006-12-27 | 2007-12-27 | Compositions and methods for treating inflammation and auto-immune diseases |
Country Status (7)
Country | Link |
---|---|
US (4) | US7931896B2 (en) |
EP (3) | EP2109455A2 (en) |
JP (4) | JP2011502954A (en) |
AU (2) | AU2007339762B2 (en) |
CA (2) | CA2673659A1 (en) |
HK (2) | HK1139070A1 (en) |
WO (2) | WO2008083239A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US9134321B2 (en) | 2006-12-27 | 2015-09-15 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0167206B1 (en) * | 1984-06-22 | 1991-10-23 | Mizusawa Industrial Chemicals Ltd. | Synthetic fraipontite and process for preparation thereof |
AU2001283507A1 (en) | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
WO2008083239A2 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
KR101429013B1 (en) * | 2007-07-02 | 2014-08-11 | 삼성전자주식회사 | Method for producing of conductive transfer roller, transfer roller thereof and image forming apparatus comprising the same |
CN102014937A (en) | 2008-03-03 | 2011-04-13 | 迈阿密大学 | Allogeneic cancer cell-based immunotherapy |
WO2010030643A1 (en) * | 2008-09-10 | 2010-03-18 | Indiana University Research And Technology Corporation | Diagnosis and prognosis of immune disorders using stat4 expression |
WO2011020024A2 (en) * | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
WO2012145568A1 (en) * | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
US20130068691A1 (en) * | 2011-08-05 | 2013-03-21 | Henry John Smith | Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
AU2012296613B2 (en) * | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
AU2014265142A1 (en) | 2013-05-17 | 2015-12-24 | Medimmune, Llc | Receptors for B7-H4 |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
CN108112254B (en) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof |
CN108473584B (en) | 2015-11-03 | 2022-01-14 | 詹森生物科技公司 | Antibodies that specifically bind to PD-1 and TIM-3 and uses thereof |
KR20200016899A (en) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | Activatable anti-PDL1 antibody, and methods of using the same |
BR112020003533A2 (en) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | b7-h4 antibodies and methods of using them |
CN112566934A (en) | 2018-01-23 | 2021-03-26 | 奈斯科尔公司 | B7-H4 antibodies and methods of use thereof |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
WO2019217657A1 (en) * | 2018-05-10 | 2019-11-14 | TympoBio, Inc. | Compositions and methods for treating autoimmune inner ear disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004000221A2 (en) * | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
US20040152105A1 (en) * | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
WO2004113500A2 (en) * | 2003-06-16 | 2004-12-29 | The University Of Washington | B7s1: an immune modulator |
WO2006133396A2 (en) * | 2005-06-08 | 2006-12-14 | Dana-Farber Cancer Institute | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US202587A (en) * | 1878-04-16 | Improvement in door-hangers | ||
US36107A (en) * | 1862-08-05 | Improvement in | ||
US12758A (en) * | 1855-04-24 | chane | ||
GB1268212A (en) * | 1968-04-19 | 1972-03-22 | Zaidan Hojin Biseibutsu | Tripeptide derivatives |
JPS6050743B2 (en) * | 1976-06-02 | 1985-11-09 | 旭光学工業株式会社 | Apatite sintered body and its manufacturing method |
US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
CH652145A5 (en) * | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4634666A (en) * | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
NL8720442A (en) * | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS. |
US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US4891719A (en) * | 1988-10-03 | 1990-01-02 | Datatape Incorporated | Fast closure method for a data signal channel |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5175099A (en) | 1989-05-17 | 1992-12-29 | Research Corporation Technologies, Inc. | Retrovirus-mediated secretion of recombinant products |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
ATE139258T1 (en) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
DE69230142T2 (en) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BINDING PAIRS |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5120727A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
WO1993001222A1 (en) | 1991-07-03 | 1993-01-21 | Kanebo, Ltd. | Thermoplastic polyurethane elastomer, method and device for manufacture thereof, and elastic fiber made therefrom |
US5202332A (en) * | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
US5162333A (en) * | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0633783B1 (en) | 1992-03-30 | 2000-06-07 | American Home Products Corporation | Rapamycin formulation for iv injection |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
ATE199392T1 (en) * | 1992-12-04 | 2001-03-15 | Medical Res Council | MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE |
DE4301681C1 (en) * | 1993-01-22 | 1994-10-20 | Deutsche Aerospace Airbus | Pipe branch between an air line and an air shower |
US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
DK0735893T3 (en) | 1993-09-14 | 2009-03-09 | Pharmexa Inc | PAN DR-binding peptides to enhance the immune response |
WO1995012972A1 (en) | 1993-11-08 | 1995-05-18 | Cressy, Wayne, Malcolm | Head restraining device |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
PL314238A1 (en) | 1993-12-17 | 1996-09-02 | Sandoz Ltd | Rapamycin derivatives |
US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ATE246808T1 (en) | 1995-11-10 | 2003-08-15 | Elan Corp Plc | PEPTIDES THAT INCREASE TRANSPORT ACROSS TISSUES AND METHODS FOR THEIR IDENTIFICATION AND USE |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
DE69707033T2 (en) * | 1996-03-05 | 2002-02-14 | Hitachi Ltd | Process for the treatment of gases containing organohalogen compositions |
WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6982323B1 (en) * | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
ES2317704T3 (en) | 1998-09-02 | 2009-04-16 | Diadexus, Inc. | A NEW METHOD FOR DIAGNOSIS, FOLLOW-UP, STAFF. IMAGINARY AND TREATMENT OF DIFFERENT CANCERES. |
US6962980B2 (en) * | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
US20030009013A1 (en) * | 1998-12-30 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6058500A (en) * | 1999-06-30 | 2001-01-31 | Center For Blood Research, The | Fusion protein and uses thereof |
DE19937656A1 (en) | 1999-08-13 | 2001-02-15 | Aventis Behring Gmbh | Use of antithrombin III for the prophylaxis and therapy of diseases |
EP1294885A2 (en) | 2000-06-30 | 2003-03-26 | Amgen, Inc. | B7-like molecules and uses thereof |
US6537968B1 (en) * | 2000-07-24 | 2003-03-25 | Alphamed Pharmaceuticals Corp | Treatment of lupus erythematosus |
AU2001283507A1 (en) * | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
US7975021B2 (en) * | 2000-10-23 | 2011-07-05 | Clearplay, Inc. | Method and user interface for downloading audio and video content filters to a media player |
US6911311B2 (en) * | 2001-01-04 | 2005-06-28 | Myriad Genetics, Inc. | Method of detecting protein-protein interactions |
EP1361893B1 (en) * | 2001-02-19 | 2012-10-24 | Merck Patent GmbH | Modified anti-egfr antibodies with reduced immunogenicity |
US20050215727A1 (en) * | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
IL150013A (en) * | 2002-06-04 | 2007-06-17 | Gil Hecht | Rotary cutting tool |
US7449300B2 (en) * | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
US7334413B2 (en) * | 2004-05-07 | 2008-02-26 | Rosemount Aerospace Inc. | Apparatus, system and method for observing combustion conditions in a gas turbine engine |
DE102004060403A1 (en) * | 2004-12-14 | 2006-07-06 | Trützschler GmbH & Co KG | Device in the spinning preparation for feeding a plurality of filling shafts, in particular mixers, with fiber material |
US7694100B2 (en) * | 2004-12-20 | 2010-04-06 | Intel Corporation | Managing system memory resident device management queues |
EP1863532A1 (en) * | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
US20070039150A1 (en) * | 2005-08-08 | 2007-02-22 | Thomas David L | Convertible furniture system comprised of modular convertible box frames and methods of forming various furniture configurations therefrom |
KR100779170B1 (en) * | 2005-08-16 | 2007-11-23 | 학교법인 포항공과대학교 | Butt coupling method with photonic quantum ring hole emitter |
JP4730263B2 (en) * | 2005-09-21 | 2011-07-20 | 富士ゼロックス株式会社 | Image processing device maintenance system |
US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
WO2008083239A2 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
CN101399708B (en) * | 2007-09-28 | 2012-04-04 | 华为技术有限公司 | Method and device for establishing network performance model |
WO2009062132A2 (en) * | 2007-11-09 | 2009-05-14 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
CN102666581A (en) * | 2009-08-31 | 2012-09-12 | 艾普利穆恩公司 | Methods and compositions for the inhibition of transplant rejection |
-
2007
- 2007-12-27 WO PCT/US2007/088979 patent/WO2008083239A2/en active Application Filing
- 2007-12-27 US US11/965,425 patent/US7931896B2/en not_active Expired - Fee Related
- 2007-12-27 JP JP2009544272A patent/JP2011502954A/en active Pending
- 2007-12-27 CA CA002673659A patent/CA2673659A1/en not_active Abandoned
- 2007-12-27 EP EP07869990A patent/EP2109455A2/en not_active Withdrawn
- 2007-12-27 EP EP20070866065 patent/EP2124998B8/en not_active Not-in-force
- 2007-12-27 US US11/965,611 patent/US20080206235A1/en not_active Abandoned
- 2007-12-27 JP JP2009544267A patent/JP5481199B2/en not_active Expired - Fee Related
- 2007-12-27 AU AU2007339762A patent/AU2007339762B2/en not_active Ceased
- 2007-12-27 EP EP12192744.6A patent/EP2586458B1/en not_active Not-in-force
- 2007-12-27 WO PCT/US2007/088960 patent/WO2008083228A2/en active Search and Examination
- 2007-12-27 AU AU2007339773A patent/AU2007339773B2/en not_active Ceased
- 2007-12-27 CA CA002673752A patent/CA2673752A1/en not_active Abandoned
-
2010
- 2010-05-31 HK HK10105325.3A patent/HK1139070A1/en not_active IP Right Cessation
- 2010-10-15 US US12/905,796 patent/US20110195073A1/en not_active Abandoned
-
2011
- 2011-03-23 US US13/070,139 patent/US20110171207A1/en not_active Abandoned
-
2013
- 2013-05-16 JP JP2013103888A patent/JP5926701B2/en not_active Expired - Fee Related
- 2013-10-31 HK HK13112247.1A patent/HK1184697A1/en not_active IP Right Cessation
-
2015
- 2015-11-25 JP JP2015229316A patent/JP2016035474A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004000221A2 (en) * | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
US20040152105A1 (en) * | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
WO2004113500A2 (en) * | 2003-06-16 | 2004-12-29 | The University Of Washington | B7s1: an immune modulator |
WO2006133396A2 (en) * | 2005-06-08 | 2006-12-14 | Dana-Farber Cancer Institute | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
Non-Patent Citations (1)
Title |
---|
SALCEDA S ET AL: "The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 306, no. 1, 15 May 2005 (2005-05-15), pages 128 - 141, XP004876369, ISSN: 0014-4827 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9134321B2 (en) | 2006-12-27 | 2015-09-15 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US9011853B2 (en) | 2009-08-31 | 2015-04-21 | Amplimmune, Inc. | B7-H4 fusion proteins and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
HK1139070A1 (en) | 2010-09-10 |
US20080160036A1 (en) | 2008-07-03 |
EP2124998A2 (en) | 2009-12-02 |
AU2007339773B2 (en) | 2011-03-10 |
WO2008083228A3 (en) | 2008-11-06 |
US20110195073A1 (en) | 2011-08-11 |
US20080206235A1 (en) | 2008-08-28 |
EP2586458B1 (en) | 2016-08-24 |
EP2124998B1 (en) | 2015-02-18 |
JP2016035474A (en) | 2016-03-17 |
WO2008083239A2 (en) | 2008-07-10 |
AU2007339773A1 (en) | 2008-07-10 |
AU2007339762A1 (en) | 2008-07-10 |
US7931896B2 (en) | 2011-04-26 |
JP2013155199A (en) | 2013-08-15 |
EP2586458A1 (en) | 2013-05-01 |
AU2007339762B2 (en) | 2011-03-31 |
CA2673659A1 (en) | 2008-07-10 |
CA2673752A1 (en) | 2008-07-10 |
WO2008083228A2 (en) | 2008-07-10 |
JP2010530354A (en) | 2010-09-09 |
US20110171207A1 (en) | 2011-07-14 |
HK1184697A1 (en) | 2014-01-30 |
JP5481199B2 (en) | 2014-04-23 |
JP5926701B2 (en) | 2016-05-25 |
JP2011502954A (en) | 2011-01-27 |
EP2124998B8 (en) | 2015-05-06 |
EP2109455A2 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008083239A3 (en) | Compositions and methods for stimulating an immune response | |
NL300914I2 (en) | Atezolizumab | |
WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
WO2011027222A3 (en) | Immunogenic compositions including tlr activity modulators | |
WO2014031487A8 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
UA104585C2 (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof | |
WO2005087238A3 (en) | Method for stimulating the immune, inflammatory or neuroprotective response | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
MX358224B (en) | Pharmaceutical composition for treatment and/or prevention of liver cancer. | |
WO2007109812A3 (en) | Immunopotentiating compounds | |
WO2009156960A3 (en) | Novel adjuvant compositions | |
WO2007079190A3 (en) | Device and method for enhancing immune response by electrical stimulation | |
WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
WO2011035205A3 (en) | Antibodies against candida, collections thereof and methods of use | |
WO2012003470A3 (en) | Antibody formulations | |
BRPI1007721B1 (en) | vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66 | |
CL2009001195A1 (en) | Immune adjuvant comprising an iap inhibitor capable of modulating immune activity; pharmaceutical composition and vaccine comprising it; method of enhancing an immune response of an individual; method of treating cancer in an individual; method of treating infection; method of treating autoimmune disorders. | |
WO2012061248A8 (en) | Novel specific hcv ns3 protease inhibitors | |
WO2007150008A3 (en) | Polypeptides from african swine virus as vaccines for preventive and therapeutic use | |
GB2453491A (en) | Immunogenic proteins of burkholderia pseudomallei and uses thereof | |
MX2012001495A (en) | Porphyromonas gingivalis polypeptides. | |
WO2010135521A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
WO2010012045A8 (en) | Influenza vaccines | |
MX2007002659A (en) | Vaccine composition against hepatitis c virus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2673752 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009544272 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007339773 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007339773 Country of ref document: AU Date of ref document: 20071227 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007869990 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07869990 Country of ref document: EP Kind code of ref document: A2 |